Press Releases Latest Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide Press Releases Year None20232022202120202019201820172016201520142013 Jul 07, 2022 Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update May 31, 2022 Theratechnologies Announces New Head of Investor Relations May 10, 2022 Appointments in Conjunction With Theratechnologies Annual Meeting May 10, 2022 Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies Apr 27, 2022 Theratechnologies to Focus Its Commercialization Activities on the North American Territory Apr 25, 2022 Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022 Apr 13, 2022 Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update Apr 08, 2022 Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR Annual Meeting 2022 Mar 31, 2022 Theratechnologies to Announce Financial Results for Its First Quarter 2022 Mar 08, 2022 Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 31 - 40 of 312
Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
Jul 07, 2022 Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update
May 10, 2022 Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies
Apr 27, 2022 Theratechnologies to Focus Its Commercialization Activities on the North American Territory
Apr 13, 2022 Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update
Apr 08, 2022 Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR Annual Meeting 2022
Mar 08, 2022 Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers
